Robert Azelby, EVP & Chief Commercial Officer at Juno Therapeutics, Inc. (JUNO), sold 3,632 shares at $44.96 ($163K) on 2017-12-18, disclosed to the SEC on 2017-12-20.
Open-market sale of $163k JUNO by EVP & Chief Commercial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.96 | 1,816 | $82K | 50.0% |
| 2 | $44.96 | 1,816 | $82K | 50.0% |
| Total | $44.96 avg | 3,632 | $163K | 100% |
| Filing → |
| JUNO | SELL | 2018-02-14 | $356K | — | Filing → |
| JUNO | SELL | 2018-02-09 | $600K | — | Filing → |
| JUNO | SELL | 2018-02-02 | $715K | — | Filing → |